Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Accolade (ACCD)
NASDAQ:ACCD
Holding ACCD?
Track your performance easily
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 08, 2024
|% Change Since: -12.34%
|Next Earnings Date:Apr 24, 2025
Earnings Call Sentiment|Neutral
Accolade reported strong revenue and cash flow performance, with significant new wins and a robust cash position. However, challenges include potential delays in health plan deployments and increased pressure from ROI guarantees.Company Guidance
During Accolade's Q2 2025 earnings call, the company highlighted several key metrics and provided forward-looking guidance. Accolade reported revenue of $106.4 million, which exceeded their guided range, and adjusted EBITDA also surpassed expectations, driven by early recognized performance guarantee (PG) revenue and effective expense management. The company generated positive free cash flow of approximately $3.1 million, ending the quarter with cash, cash equivalents, and marketable securities totaling over $234 million, positioning them with a net cash position of more than $23 million. For Q3, Accolade anticipates revenue between $104 million and $107 million and an adjusted EBITDA loss ranging from $3 million to $5 million. They reaffirmed their full-year guidance with projected revenue of $460 million to $475 million and adjusted EBITDA between $15 million and $20 million. The company emphasized a focus on profitability, expecting to double adjusted EBITDA over the next two years and continue generating positive cash flow.Revenue Exceeds Expectations
Accolade reported Q2 revenue of $106.4 million, surpassing the top of the guidance range.
Positive Cash Flow
The company generated positive free cash flow of approximately $3.1 million.
Strong Market Demand
Accolade noted strong demand across all segments, including strategic, enterprise, health plans, and government.
Significant New Wins
Accolade secured a notable competitive takeaway deal for 2nd.MD in the expert medical opinion space.
Strong Cash Position
Accolade ended the quarter with over $234 million in cash, cash equivalents, and marketable securities, improving its net cash position by nearly $20 million compared to the previous year.
---
ACCD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACCD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 08, 2024 | $3.97 | $4.04 | +1.76% |
| Jun 27, 2024 | $6.39 | $3.58 | -43.97% |
| Apr 25, 2024 | $9.19 | $7.89 | -14.15% |
| Jan 09, 2024 | $14.99 | $15.02 | +0.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Accolade (ACCD) report earnings?
Accolade (ACCD) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Accolade (ACCD) earnings time?
Accolade (ACCD) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACCD EPS forecast?
Currently, no data Available
---
